Remepy Reports Strong Hybridopa Parkinson’s Trial Data
NEW YORK, N.Y., May 20, 2026 Remepy has announced positive results from its Phase IIa clinical trial evaluating Hybridopa™,...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
NEW YORK, N.Y., May 20, 2026 Remepy has announced positive results from its Phase IIa clinical trial evaluating Hybridopa™,...
VANCOUVER, British Columbia, May 20, 2026 Optimi Health Corp. has announced the pricing of an oversubscribed US$15 million underwritten...
BOSTON, Mass., May 20, 2026 The Paragon Institute has released a new scientific proposal highlighting the growing risks associated...
